Addition of Quell® Platform Broadens electroCore’s Bioelectronic Technology Portfolio and Accelerates Growth in Chronic Pain and Wellness MarketsROCKAWAY, N.J., May 02, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (“ECOR,” “electroCore,” or the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic technology company, announced today the completion of the merger (the “Merger”) with NeuroMetrix, Inc. (“NeuroMetrix” or “NURO”) (Nasdaq: NURO), positioning itself as a diversified leader in non-invasive healt ...

ROCKAWAY, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that its flagship wellness product, Truvaga Plus, now works with the Apple® Health app. Truvaga Plus is a hand-held vagus nerve stimulator designed to elevate the day-to-day experience through quick and gentle activation of your vagus nerve. The product is designed to provide stress relief, improve sleep, enhance peace of mind and improve focus. D ...

ROCKAWAY, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic technology company, announced today that it will report financial results for the first quarter ended March 31, 2025, after the close of the market on Wednesday, May 7, 2025. Management will host a webinar at 4:30 PM EST to review the financial results and answer questions. Investors can access the webinar using the details below: Wednesday, May 7, 4:30 PM ESTDial-In: (646) 931-3860Webinar I ...

ROCKAWAY, N.J., April 17, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that new data presented at the 2025 International Brain Injury Association World Congress highlights the effectiveness of gammaCore® non-invasive vagus nerve stimulation (nVNS) in treating concussive symptoms associated with mild traumatic brain injury (mTBI). Dr. Michael Ament of Cherry Creek Neurology presented his study entitled, "Adjunctive N ...

Dan Goldberger, CEO, will host a group presentation on Wednesday, April 23, 2025 at 1:30 p.m. PT and host one-on-one meetings throughout both days. To schedule a one-on-one meeting with Mr. Goldberger, investors are encouraged to reach out to Planet MicroCap or electroCore's investor relations at ecor@fnkir.com. About electroCore, Inc. electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation ("nVNS") te ...

ROCKAWAY, N.J., April 03, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, has been recognized by the Financial Times as one of “The Americas’ Fastest Growing Companies 2025.” Debuting at number 125, electroCore joins 300 other companies dominating in their respective sectors. This is the sixth annual list that the Financial Times published, ranking companies based on the highest compound annual revenue growth between the years 2020 a ...

Dan Goldberger, CEO and Joshua Lev, Chief Financial Officer, will host a group presentation at 2:15 p.m. ET and participate in one-on-one meetings throughout the day. electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation ("nVNS") technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings util ...

ROCKAWAY, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that electroCore has received a new Federal Supply Schedule (FSS) contract, with an effective date of June 15, 2025 and running through June 14, 2030. "Obtaining a follow-on contract in this macro environment is a tremendous vote of confidence by the Veterans Affairs (VA) FSS Service, demonstrating that gammaCore continues to be a cost effective ...

Financial Data and Key Metrics Changes - Revenue for 2024 was $25.2 million, up 57% from $16 million in 2023 [35] - Fourth quarter revenue was $7 million, marking a 36% increase over the same quarter last year [9] - Full year gross margins improved to 85% from 83% in the previous year [10] - Net loss for 2024 narrowed by 37% to $11.9 million compared to $18.8 million in 2023 [38] - Cash, cash equivalents, and marketable securities totaled approximately $12.2 million at year-end 2024, up from $10.6 million in 2023 [39] Business Line Data and Key Metrics Changes - Sales in the VA channel grew 85% to $17.8 million in 2024 from $9.6 million in 2023 [14] - Truvaga net sales reached $2.8 million in 2024, a 174% increase over 2023 [16] - TAC-STIM sales were $1.2 million for the full year, down from $1.7 million in the previous year [20] - U.S. prescription gammaCore channel recorded revenue of $1.5 million, down 15% from 2023 [22] Market Data and Key Metrics Changes - Approximately 30 million covered lives in the U.S. for the prescription headache business [12] - Revenue from channels outside the U.S. was flat at $1.9 million for 2024 [24] - The VA Hospital System remains the largest customer, with 170 facilities purchasing gammaCore products [15] Company Strategy and Development Direction - The company aims to become a leader in the bioelectronic health and wellness sector through acquisitions like NeuroMetrix [25] - Plans to leverage existing sales channels for new products, including Quell for fibromyalgia and Sparrow for opioid withdrawal [28][32] - Focus on expanding Truvaga's market presence through e-commerce and partnerships [49] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about long-term prospects, citing growth in prescription products and wellness offerings [42] - The company is aware of macroeconomic disruptions affecting VA hospital customers but has not seen direct impacts on business cadence [46] - Future growth is expected from prescription gammaCore sales and direct-to-consumer initiatives [118] Other Important Information - The company plans to maintain discipline around operating expenses while investing in growth [55] - The acquisition of NeuroMetrix is expected to close in Q2 2025, enhancing the product portfolio [26] - The company is exploring international expansion for Truvaga products [125] Q&A Session Summary Question: Plans for selling the Quell product post-acquisition - The company plans to integrate Quell into existing sales channels and provide training to the sales team after the acquisition closes [62][64] Question: Update on Joerns and its growth - The company acknowledges slower traction with Joerns but is seeing early signs of growth with more prescribers [80] Question: Comparison of Kaiser channel to VA system - The Kaiser channel is more challenging to penetrate but once established, it is expected to be a sticky business [89] Question: Future growth opportunities - The company sees potential in prescription gammaCore sales, direct-to-consumer growth, and new product acquisitions [118] Question: Impact of VA personnel reductions - No material impact observed yet, but the situation is being monitored closely [126] Question: Confidence in achieving mid-80s gross margin - The company expects to maintain mid-80s gross margins in 2025, primarily from existing products [129] Question: Plans for Truvaga sales growth - The company is focusing on omnichannel distribution, including e-commerce and influencer marketing [146]

electroCore (ECOR) Q4 2024 Earnings Call March 12, 2025 05:30 PM ET Company Participants Daniel Goldberger - CEO & DirectorJoshua Lev - Chief Financial OfficerAnthony Vendetti - Executive Managing Director Conference Call Participants Tyler Bussian - Equity Research AnalystNone - Analyst Operator Recording in progress. And welcome to the ElectriCore Fourth Quarter and Full Year twenty twenty four Earnings Conference Call. As part of our ongoing efforts to reduce costs and drive profitability, management has ...